Development and internal-external validation of an interpretable machine learning model integrating clinical and polygenic predictors for coronary artery disease: a multicenter retrospective cohort study.

BACKGROUND

Accurate primary-prevention risk stratification for coronary artery disease (CAD) remains challenging. We developed and internally validated a framework integrating clinical variables with a polygenic risk score (PRS).

METHODS

This three-center retrospective cohort included 2,067 adults without baseline CAD. The primary target was 5-year CAD cumulative incidence, with non-coronary death treated as a competing event. Clinical, PRS-only, and integrated cause-specific eXtreme Gradient Boosting (XGBoost) models were evaluated using leave-one-center-out internal-external validation. Performance assessment included cumulative/dynamic area under the curve (AUC), inverse-probability-of-censoring-weighted Brier score, calibration, and competing-risk decision-curve analysis. PRS associations were estimated using Fine-Gray regression, and model behavior was examined using SHapley Additive exPlanations (SHAP).

RESULTS

During a median follow-up of 6.8 years, 215 participants experienced the primary endpoint; 163 events occurred within 5 years, and the 5-year cumulative incidence was 8.4%. Each 1-SD increase in the principal component-adjusted PRS was associated with the primary endpoint (adjusted subdistribution hazard ratio, 1.37; 95% CI, 1.21-1.55; p < 0.001). Based on pooled out-of-center predictions, the integrated model had a 5-year AUC of 0.779 (95% CI, 0.746-0.812), compared with 0.762 (95% CI, 0.728-0.796) for the clinical model; the difference was 0.017 (95% CI, -0.003-0.038). Its Brier score was 0.071, observed-to-expected ratio was 1.01, and calibration slope was 0.97. The integrated model showed a small net-benefit advantage over the clinical model at thresholds of approximately 8%-15%. SHAP ranked PRS, age, and low-density lipoprotein cholesterol highest and showed a concordant interaction pattern between PRS and low-density lipoprotein cholesterol. Five-year cumulative incidences were 2.7%, 7.2%, and 19.8% in the prespecified low-, intermediate-, and high-risk categories (Gray's test p < 0.001).

CONCLUSIONS

The PRS was independently associated with incident CAD. Integration with clinical variables yielded a modest, statistically uncertain improvement in discrimination and satisfactory calibration during internal-external validation. External validation is required before clinical implementation.